Navigation Links
Dry beans inhibit development of mammary cancer
Date:2/4/2009

Madison, WI, February 2, 2009 - As the world seeks new ways to prevent and treat chronic diseases such as diabetes, heart disease and cancer, more research continues to be conducted on the benefits of certain foods in reducing people's risk of contracting these ailments. Legumes in particular are often cited as being high in antioxidants, which have the property of being able to fight off free radical cells within the body, reducing the risk of cancer and other chronic diseases. A recent study further investigated these connections, as researchers focused on the benefits of one type of legume, dry beans, in reducing the risk of mammary cancer.

To address whether dry bean consumption is associated with a reduction in mammary cancer, scientists at Colorado State University studied the anticancer activity of six market classes of bean including; small red, great northern, navy, black, dark red and white kidney bean in the diet of laboratory animals. They also evaluated whether the level of antioxidants or seed coat pigments in the bean were related to mammary cancer. The study was funded by a grant from the Beans for Health Alliance, and the Colorado Agricultural Experiment Station with assistance from Archer Daniels Midland Co. and Bush Brothers Inc. Results from the study were published in the January-February 2009 issue of the journal Crop Science.

Cooked dry bean powder from the six market classes and a control group without beans in the diet were fed to laboratory rats in a standard preclinical model for breast cancer. The dry bean powders were also evaluated for antioxidant capacity, phenolic and flavonoid content; all factors thought to be associated with anticancer activity. Chemical analysis of the beans revealed that total phenolic and flavonoid content varied widely among market classes and the differences were strongly associated with seed coat color; where colored beans had ten times or greater phenolic and flavonoid content compared to white beans. Antioxidant capacity of the beans also varied widely among dry bean market classes and were highly related to seed coat color, where colored beans had approximately two to three times greater antioxidant capacity than white beans.

Dry bean consumption from every market class reduced cancer incidence (number of animals with one tumor) and tumor number per animal compared to the control group. Cancer incidence was reduced from 95% in the control group to 67% in animals fed beans. The average number of malignant tumors was also reduced from 3.2 in the control group to 1.4 tumors per animal in the group fed bean. No associations were observed between phenolic content, flavonoid content and antioxidant capacity with cancer among the bean market classes. These results clearly suggest that the anticancer activity in dry bean is not associated with seed color or antioxidant capacity.

Research is ongoing at Colorado State University to investigate the mechanisms and molecules that contribute to the anticancer properties of dry bean. Clinical trials are also underway to determine if bean in the diet of humans are associated with biomarkers for cancer incidence.


'/>"/>

Contact: Sara Uttech
suttech@crops.org
608-268-4948
Crop Science Society of America
Source:Eurekalert

Related medicine news :

1. Black Caribbeans do better in America than in England
2. Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
3. Coffee Beans May Be Newest Stress-Buster
4. Potent peptides inhibit HIV entry into cells
5. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
6. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
7. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
10. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
11. Silencing small but mighty cancer inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: